論文 - 詳細
| RRC ID | 62953 |
|---|---|
| 著者 | Liu W, Takahashi Y, Morishita M, Nishikawa M, Takakura Y. |
| タイトル | Development of CD40L-modified tumor small extracellular vesicles for effective induction of antitumor immune response. |
| ジャーナル | Nanomedicine (Lond) |
| Abstract |
Aim: Tumor-derived small extracellular vesicles (TEVs) are considered for use in inducing tumor antigen-specific immune responses as they contain tumor antigens. The delivery of tumor antigens to the antigen presentation cells (especially dendritic cells [DCs]), and the activation of DCs are the main challenges of TEV therapy. Materials & methods: TEVs were modified with CD40 ligand (CD40L), which can target CD40 expressed on the surface of DCs and can activate them via CD40L-CD40 interactions. Results: It was found that CD40L-TEVs were efficiently taken up by DCs and also activated them. Moreover, tumor antigens were efficiently presented to the T cells by DCs treated with CD40L-TEVs. Conclusion: This study proved that CD40L-modification of TEVs will be helpful for further development of TEV-based tumor vaccination. |
| 巻・号 | 15(17) |
| ページ | 1641-1652 |
| 公開日 | 2020-7-1 |
| DOI | 10.2217/nnm-2020-0071 |
| PMID | 32664826 |
| MeSH | CD40 Ligand* Dendritic Cells Extracellular Vesicles* Humans Immunity Neoplasms* / therapy |
| IF | 4.3 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | X(Twitter) |
| 各媒体での言及数の合計 | 1 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | B16/BL6(RCB2638) |